[RinaseaofDs]

I don’t dispute anything you are saying. More cures are better, especially in the realm of virology.

However, why a 900 point move to the upside in the market, and the breathlessness of the people reporting it in the media?

The risk involved in a novel treatment like this is orders of magnitude higher than with HCQ/Zinc which Fauci has been throwing shade on since the get-go.

The entire reason we have an FDA is Thalidomide. Great drug, and then over time you find out it maims kids in the womb.

HCQ is relatively safer, by a wide margin. Why the continuing shade?

[Rockingham]

Remdesivir is closer to approval for COVID-19 therapy because it was developed as an intended HIV remedy. It flunked effectiveness trials for HIV but passed as safe in that context. Depending on Remdesivir's detailed mechanism of action, it could be projected to be a safer and more effective antiviral than the HCQ/Zinc/Antibiotics cocktail. From what I have read, that therapy works best if administered before breathing is impaired in a major way. It may be that Remdesivir could work even in such advanced cases, just as Ivermectin is said to do.

Nevertheless, the larger issues of the slowness of the FDA approval process and the distorted incentives in drug development remain. With a mandate to help develop new drugs, the FDA loves Remdesivir, the new, bright and shiny thing, but scorn old, previously approved remedies like HCQ/Zinc/Antibiotics and Ivermectin. The stock market seems to recognize that and is cheered by the advance of Remdesivir through the FDA approval process.